CareLit · DOI-Nachweis · Pneumologie
Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis
DOI 10.1055/s-0035-1544828
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, L Richeldi, A Azuma, Y Inoue, HR Collard, I Tschoepe, S Stowasser, M Selman
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: The two replicate randomized, double-blind, placebo-controlled, 52-week Phase III INPULSIS™ trials assessed the efficacy and safety of nintedanib 150 mg twice daily in patients with IPF. Nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in mL/year, the primary endpoint, in both trials (p < 0.001 for both), consistent with slowing disease progression. Statistically…
Zitieren
Zitierempfehlung
U Costabel, L Richeldi, A Azuma, Y Inoue, HR Collard, I Tschoepe, S Stowasser, M Selman (2015) Pre-specified subgroup analyses of pooled data from the INPULSIS™ trials of nintedanib in idiopathic pulmonary fibrosis. Pneumologie (02). https://doi.org/10.1055/s-0035-1544828
Mit CareLit weiterarbeiten